Compare Organon Pharma Indonesia Tbk. (SCPI) vs Chandra Asri Pacific Tbk. (TPIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon Pharma Indonesia Tbk. vs Chandra Asri Pacific Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Chandra Asri Pacific Tbk. trades at Rp1,880 (market cap 166.97T, 197.42M 24h volume). The key difference: Chandra Asri Pacific Tbk. is far larger — about 1599.3× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | TPIA | |
|---|---|---|
Market Cap | 104.4B | 166.97T |
Volume | — | 197.42M |
Lot | — | 1.97M |
Turnover | — | 373.29B |
Average Price | — | 1,890.87 |
Value | — | 373.29B |
Indicative Equilibrium Price | — | 1,880 |
Indicative Equilibrium Volume | — | 33.45K |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →About Chandra Asri Pacific Tbk.
PT Chandra Asri Petrochemical Tbk formerly PT. Tri Polyta Indonesia, Tbk (the Company) was established under the Domestic Capital Investment Law No. 6 year 1968 and Law No. 12 year 1970 by Notarial Deed No. 40 dated November 2, 1984 of Ridwan Suselo, S.H., notary public in Jakarta. The Company is the largest Indonesia producer of polypropyleneresins that are used in the manufacture of a wide range of consumer products.
Read more on TPIA →
